Dina Ramadane
Stock Analyst at Bank of America Securities
(1.16)
# 3,798
Out of 5,081 analysts
31
Total ratings
36.8%
Success rate
-2.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dina Ramadane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Reiterated: Buy | $60 | $28.30 | +112.01% | 13 | Oct 23, 2026 | |
| BHVN Biohaven | Reiterated: Sell | $11 | $14.45 | -23.88% | 10 | Oct 12, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $45 | $28.17 | +59.74% | 3 | Oct 12, 2026 | |
| PROK ProKidney | Reiterated: Sell | $1 | $1.36 | -26.47% | 4 | Oct 12, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $22 | $27.09 | -18.79% | 1 | May 7, 2026 |
Vera Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $60
Current: $28.30
Upside: +112.01%
Biohaven
Oct 12, 2026
Reiterated: Sell
Price Target: $11
Current: $14.45
Upside: -23.88%
Immunovant
Oct 12, 2026
Reiterated: Buy
Price Target: $45
Current: $28.17
Upside: +59.74%
ProKidney
Oct 12, 2026
Reiterated: Sell
Price Target: $1
Current: $1.36
Upside: -26.47%
Amylyx Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $22
Current: $27.09
Upside: -18.79%